64th ASH Annual Meeting and Exposition: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: B-lineage ALL: Molecular Characterization and Targeted Therapies

Symposia: Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Lymphoid Leukemias, ALL, Research, Biological therapies, artificial intelligence (AI), Antibody Therapy, Fundamental Science, adult, Bispecific Antibody Therapy, Translational Research, CHIP, assays, genomics, bioinformatics, Combination therapy, Clinical Research, pediatric, Diseases, Therapies, immunology, Immunotherapy, clinical procedures, Lymphoid Malignancies, computational biology, Biological Processes, Monoclonal Antibody Therapy, Technology and Procedures, Study Population, profiling, Human, Minimal Residual Disease , Animal model, machine learning, molecular testing, omics technologies

Great Hall AD (Ernest N. Morial Convention Center)

Moderators:

Zaid Abdel Rahman, MD, University of North Dakota and Jessica Leonard, MD, Oregon Health and Science University

Disclosures:

Leonard: Pfeizer: Consultancy; Adaptive: Consultancy; AbbVie: Research Funding; Amgen: Research Funding; KiTE: Consultancy; Takeda: Consultancy.

9:30 AM

433

PAX5 Epigenetically Orchestrates CD58 Transcription and Modulates Blinatumomab Response in Acute Lymphoblastic Leukemia

Yizhen Li, PhD¹, Takaya Moriyama, MD, PhD², Satoshi Yoshimura³^*, Xuijie Zhao⁴^*, Zhenhua LI⁴^*, Xu Yang, PhD⁵^*, Jacob A Steele⁶^*, Shondra Miller⁷^*, Elisabeth Paietta, PhD⁸, Marina Konopleva, MD, PhD⁹, Jiyang Yu, Ph.D.⁵^*, Hiroto Inaba, MD, PhD¹⁰, Raul C Ribeiro, MD¹⁰^*, Ching-Hon Pui, MD¹¹ and Jun J. Yang, PhD¹²

¹Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
²Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Bartlett, TN
³Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis
⁴Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN
⁵Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
⁶Center for Advanced Genome Engineering, St Jude Children's Research Hospital, Memphis, TN
⁷Center for Advanced Genome Engineering (CAGE), St Jude Children's Research Hospital, Memphis, TN
⁸Cancer Center, Montefiore Medical Center, Bronx, NY
⁹Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
¹⁰Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
¹¹Department of Oncology, St. Jude Children's Rsch./Hosp., Memphis, TN
¹²Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN

9:45 AM

434

CD58 Could be As a Leukemic Marker in Relapsed/Refractory B-ALL Patients after Multiline Therapies

Xinjian Yu, MD¹^*, Pan Li²^*, Heyuan Feng²^*, Jian Kang²^*, Yafeng Li²^*, Xichang Zheng²^*, Tong Wu, MD³ and Shuangyou Liu²^*

¹Medical Laboratory, Beijing Boren Hospital, Beijing, China
²Beijing Boren Hospital, Beijing, China
³Department of Hematology, Beijing GoBroad Boren Hospital, Beijing, China

10:00 AM

435

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Lennart Lenk, PhD¹^*, Irène Baccelli, PhD²^*, Dorothee Winterberg, PhD¹^*, Anna Dietterle¹^*, Frédérique Corallo, MD²^*, Julien Taurelle²^*, Emma Narbeburu²^*, Anna Laqua, PhD³^*, Beat Bornhauser, PhD⁴^*, Jean-Pierre Bourquin, MD, PhD⁵, Fotini Vogiatzi, PhD¹^*, Martin Schrappe, MD¹, Gunnar Cario⁶^*, Monika Brüggemann, MD³^*, Nicolas Poirier, PhD²^* and Denis Martin Schewe, MD⁷^*

¹Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
²OSE Immunotherapeutics, Nantes, France
³Department of Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany
⁴Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland
⁵University Children's Hospital Zurich, Zurich, Switzerland
⁶Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Kiel, Germany
⁷Department of Pediatrics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

10:15 AM

436

Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children’s Oncology Group Study

Xiaotu Ma, PhD¹^*, Lingyun Ji^2,3^*, Yanling Liu, PhD⁴^*, Ying Shao⁴^*, Heather Mulder, BS⁴^*, Pandurang Kolekar, Ph.D⁴^*, Quang Tran, PhD¹, Jinghui Zhang, PhD⁴^*, John Easton, PhD⁴^*, William L. Carroll, MD^5,6, Patrick A. Brown, MD⁷ and Mignon L. Loh, MD⁸

¹St. Jude Children's Research Hospital, Memphis, TN
²Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA
³Children's Oncology Group, Monrovia, CA
⁴Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
⁵Perlmutter Cancer Center and Department of Pediatrics, NYU Langone Health, New York, NY
⁶Department of Pathology, New York University Langone Medical Center, New York, NY
⁷Division of Pediatric Oncology, Johns Hopkins Univ., Baltimore, MD
⁸Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute and Department of Pediatrics, Seattle Children’s Hospital, University of Washington, Seattle, WA

10:30 AM

437

Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Caner Saygin, MD¹, Jacob Stauber²^*, Ibrahim Aldoss, MD³, Adam S. Sperling, MD, PhD⁴, Lachelle D. Weeks, MD, PhD⁵, Marlise R. Luskin, MD⁵, Todd C. Knepper, PharmD⁶, Pankhuri Wanjari⁷^*, Peng Wang, MD⁷^*, Angela Lager, PhD⁷^*, Jeremy Segal, MD, PhD⁷^*, Benjamin Kaumeyer, MD⁷^*, Sandeep Gurbuxani, MBBS, PhD⁷, Girish Venkataraman, MD, MBBS⁷, Jason Xiaojun Cheng, MD, PhD⁷, Bartholomew Eisfelder, PhD⁸^*, Oliver Bohorquez²^*, Anand Ashwin Patel, MD⁸, Olatoyosi Odenike, MD⁸, Richard A. Larson, MD⁸, Lucy A. Godley, MD, PhD⁸, Daniel A. Arber, MD⁷, Benjamin L. Ebert, MD, PhD⁵, John M. Greally, MB, PhD⁹^*, Ulrich G. Steidl, MD, PhD², Bijal D. Shah, MD¹⁰ and Wendy Stock, MD⁸

¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
²Albert Einstein College of Medicine, Bronx, NY
³City of Hope Comprehensive Cancer Center, Duarte
⁴Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Moffitt Cancer Center, Tampa, FL
⁷Department of Pathology, The University of Chicago, Chicago, IL
⁸Section of Hematology/Oncology, University of Chicago, Chicago, IL
⁹Center for Epigenomics, Department of Genetics, Albert Einstein College of Medicine, Bronx, NY
¹⁰H. Lee Moffitt Cancer Center, Tampa, FL

10:45 AM

438

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Thomas Beder¹^*, Björn Thore Hansen¹^*, Alina M. Hartmann¹^*, Johannes Zimmermann²^*, Eric Amelunxen¹^*, Nadine Kraft¹^*, Wencke Walter, PhD³^*, Marketa Zaliova⁴, Zeljko Antic⁵^*, Philippe Chouvarine⁵^*, Lorenz Bartsch¹^*, Miriam Bultmann¹^*, Sonja Bendig¹^*, Jan Kässens¹^*, Sören Franzenburg⁶^*, Christoph Kaleta²^*, Andre Franke⁶^*, Gunnar Cario⁷^*, Martin Schrappe, MD⁷, Martin Neumann¹^*, Nicola Goekbuget, MD⁸, Anke K. Bergmann, MD⁵^*, Jan Trka⁴, Claudia Haferlach, MD³, Monika Brüggemann, MD¹^*, Claudia D. Baldus, MD¹^* and Lorenz Bastian¹^*

¹Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Kiel, Germany
²Institute of Experimental Medicine, Research Group Medical Systems Biology, Kiel University, Kiel, Germany
³MLL Munich Leukemia Laboratory, Munich, Germany
⁴CLIP - Childhood Leukaemia Investigation Prague, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
⁵Department of Human Genetics, Hannover Medical School (MHH), Hannover, Germany
⁶Institute for Clinical Molecular Biology Kiel, Kiel University, Kiel, Germany
⁷Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Kiel, Germany
⁸Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

618.O2.6 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: B-lineage ALL: Molecular Characterization and Targeted Therapies